Apply to join
Member Sign In
Member Sign Out
Cell & Gene Therapy
Apply to Join
Science In Brief
SAB Biotherapeutics begins seasonal flu immunotherapy clinical trial
SAB Biotherapeutics has begun a phase I clinical trial evaluating SAB-176 for the treatment of seasonal influenza.
J&J reports positive preclinical results for COVID-19 vaccine
Johnson & Johnson reported that its lead COVID-19 vaccine candidate protected against SARS-CoV-2 in preclinical studies.
Inovio reports long-term positive results for COVID-19 vaccine
Inovio released results of a nonhuman primate study for its COVID-19 DNA vaccine, Ino-4800. The vaccine protected the animals 13 weeks after vaccinations and mediated T- and B-cell immune responses, according to the firm.
Intravacc, Celonic to jointly develop COVID-19 vaccine
Vaccine development firm Intravacc and biopharmaceutical contract development and manufacturing organization Celonic are teaming up to develop a COVID-19 vaccine.
UCB, Roche to develop antibodies for Alzheimer's disease
Biopharmaceutical firm UCB has signed a deal to provide Roche and Genentech with an exclusive, worldwide license to its UCB0107 antitau antibody treatment for people living with Alzheimer's disease.
Omega Therapeutics advances epigenomic programming platform
Omega Therapeutics has received $85 million in financing to support clinical trials of its epigenomic controllers for programs in oncology, inflammation, autoimmune, metabolic, and rare genetic diseases.
Truebinding licenses gene-editing platform from Horizon Discovery
TrueBinding has signed a set of commercial licenses for the use of Horizon Discovery's current good manufacturing practice-compliant Chosource platform.
Avacta, Daewoong partner on COVID-19 therapy
Avacta has expanded its collaboration with Daewoong Pharmaceutical to develop stem cell treatments using Avacta's neutralizing Affimer therapy for COVID-19 patients.
Constant Therapeutics to begin U.S. phase II clinical trial of COVID-19 therapy
Constant Therapeutics will begin a phase II clinical trial of the peptide drug TXA127 at Columbia University Irving Medical Center in New York City for the treatment of COVID-19.
ASU, World Economic Forum launch business survey for COVID-19
Arizona State University (ASU) and the World Economic Forum have launched COVID-19 Diagnostics Commons, a project that will survey businesses and share knowledge about how to safely and effectively bring employees back to work.
Exclusive content for Science Advisory Board members on trends and outcomes that are influencing the future of scientific research.
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Earn points for contributing to research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Tweets by @ScienceBoard